The latest price target for Monopar Therapeutics (NASDAQ:MNPR) was reported by HC Wainwright & Co. on November 11, 2024. The analyst firm set a price target for $22.00 expecting MNPR to fall to within 12 months (a possible -6.88% downside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Monopar Therapeutics (NASDAQ:MNPR) was provided by HC Wainwright & Co., and Monopar Therapeutics maintained their buy rating.

The last upgrade for Monopar Therapeutics Inc happened on April 11, 2024 when JonesTrading raised their price target to $2. JonesTrading previously had a hold for Monopar Therapeutics Inc.

The last downgrade for Monopar Therapeutics Inc happened on March 29, 2023 when Maxim Group changed their price target from N/A to N/A for Monopar Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monopar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monopar Therapeutics was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest Monopar Therapeutics (MNPR) rating was a maintained with a price target of $6.00 to $22.00. The current price Monopar Therapeutics (MNPR) is trading at is $23.63, which is out of the analyst’s predicted range.